HONG KONG, Aug. 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The clearance allows initiation of...
Advanced Capsule Technology for Improved Digestive Enzyme Delivery SEOUL, South Korea, Aug. 5, 2026 /PRNewswire/ -- Lonza Capsugel has released new peer-reviewed research...